SynthesisScientific reports2019
Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis.
Synthesis in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Tumour-infiltrating lymphocytes: from prognosis to treatment selection.British journal of cancer · 2023Pooled it
- Associations Between Body Composition and Intratumoural Immune Cells in Patients With Uterine Cervical Cancer.Journal of cachexia, sarcopenia and muscle · 2026Article
- Is Ultrahigh Dose Rate Critical for the Effectiveness of Microbeam Radiation Therapy in a Broad-Beam Combined Treatment?Advances in radiation oncology · 2026Article
- The complexities of PD-L1 expression as an indicator of immunotherapy outcomes.Immunotherapy · 2025Article
- Keeping it local: how CD8 TRMs regulate viral and cancer immunity.Frontiers in immunology · 2025Review
- Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling.Frontiers in immunology · 2025Review
- Review
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Nature cancer · 2024Article
- Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting.Nature biomedical engineering · 2023Article
- Retinoic Acid-Related Orphan Receptor α Is Required for Generation of Th2 Cells in Type 2 Pulmonary Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Eribulin mesylate exerts antitumor effects via CD103.Oncoimmunology · 2023Article
- Prognostic value of CD103Oral oncology · 2022Article
- The multifunctional nature of CD103 (αEβ7 integrin) signaling in tissue-resident lymphocytes.American journal of physiology. Cell physiology · 2022Review
- The genomic and transcriptional landscape of primary central nervous system lymphoma.Nature communications · 2022Article
- When secretion turns into excretion - the different roles of IgA.Frontiers in immunology · 2022Review
- Characterization of spleen and lymph node cell typesFrontiers in molecular neuroscience · 2022Article
- The Landscape of the Tumor-Infiltrating Immune Cell and Prognostic Nomogram in Colorectal Cancer.Frontiers in genetics · 2022Article
- Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients.Oncoimmunology · 2021Article
- Hypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program.JCI insight · 2021Article
- Tumor-infiltrating lymphocytes in the immunotherapy era.Cellular & molecular immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD103 is a transmembrane heterodimer complex that mediates cell adhesion, migration, and lymphocyte homing of cell through interaction with E-cadherin. Recently, CD103+ immune cells in human carcinoma has been investigated as a prognostic factor, however, the correlation between CD103+ immune cells and survival are still elusive. Therefore, a meta-analysis was performed to determine the prognostic value of CD103+ immune cells in solid tumor. Studies relevant to the subject was searched from PubMed, Embase, and Web of Science. Ten studies including 2,824 patients were eligible for the analysis. Tumors positive for CD103+ immune cells were associated with favorable overall survival, disease-free survival, and disease-specific survival. Subgroup analysis revealed that assessing CD103+ immune cells in epithelial and total (both epithelial and stromal) areas or using whole slide section were associated with good prognosis. Furthermore, stromal CD103+ immune cells or CD103+ immune cells evaluated by tissue microarrays were not always significantly prognostic. In conclusion, these results show that CD103+ immune cells are associated with prognosis in solid tumor. However, the region of assessment and selection of material for the evaluation could affect the value of CD103 as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.